Literature DB >> 33804204

Macrophage Plasticity and Function in the Lung Tumour Microenvironment Revealed in 3D Heterotypic Spheroid and Explant Models.

Lauren Evans1, Kate Milward1, Richard Attanoos2,3, Aled Clayton1, Rachel Errington1, Zsuzsanna Tabi1.   

Abstract

In non-small cell lung cancer (NSCLC), stroma-resident and tumour-infiltrating macrophages may facilitate an immunosuppressive tumour microenvironment (TME) and hamper immunotherapeutic responses. Analysis of tumour-associated macrophage (TAM) plasticity in NSCLC is largely lacking. We established a novel, multi-marker, dual analysis approach for assessing monocyte-derived macrophage (Mφ) polarisation and M1/M2 phenotypic plasticity. We developed a flow cytometry-based, two-marker analysis (CD64 and CD206) of CD14+ cells. The phenotype and immune function of in vitro-induced TAMs was studied in a heterotypic spheroid and tumour-derived explant model of NSCLC. Heterotypic spheroids and NSCLC explants skewed Mφs from an M1- (CD206loCD64hi) to M2-like (CD206hiCD64lo) phenotype. Lipopolysaccharide (LPS) and IFNγ treatment reversed M2-like Mφ polarisation, indicating the plasticity of Mφs. Importantly, antigen-specific CD8+ T cell responses were reduced in the presence of tumour explant-conditioned Mφs, but not spheroid-conditioned Mφs, suggesting explants are likely a more relevant model of the immune TME than cell line-derived spheroids. Our data indicates the importance of multi-marker, functional analyses within Mφ subsets and the advantages of the ex vivo NSCLC explant model in immunomodulation studies. We highlight the plasticity of the M1/M2 phenotype using the explant model and provide a tool for studying therapeutic interventions designed to reprogram M2-like Mφ-induced immunosuppression.

Entities:  

Keywords:  NSCLC; heterotypic spheroids; myeloid cells; tumour explants; tumour microenvironment

Year:  2021        PMID: 33804204      PMCID: PMC7999110          DOI: 10.3390/biomedicines9030302

Source DB:  PubMed          Journal:  Biomedicines        ISSN: 2227-9059


  49 in total

1.  Characterization of M1/M2 Tumour-Associated Macrophages (TAMs) and Th1/Th2 Cytokine Profiles in Patients with NSCLC.

Authors:  S A Almatroodi; C F McDonald; I A Darby; D S Pouniotis
Journal:  Cancer Microenviron       Date:  2015-08-30

Review 2.  Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment.

Authors:  Thomas F Gajewski; Mercedes Fuertes; Robbert Spaapen; Yan Zheng; Justin Kline
Journal:  Curr Opin Immunol       Date:  2010-12-23       Impact factor: 7.486

3.  Tumor-associated macrophages: the double-edged sword in cancer progression.

Authors:  Jeremy J W Chen; Yi-Chen Lin; Pei-Li Yao; Ang Yuan; Hsang-Yu Chen; Chia-Tung Shun; Meng-Feng Tsai; Chun-Houh Chen; Pan-Chyr Yang
Journal:  J Clin Oncol       Date:  2004-12-14       Impact factor: 44.544

4.  Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+ PD-L1+ phenotype in prostate cancer.

Authors:  Lisa K Spary; Josephine Salimu; Jason P Webber; Aled Clayton; Malcolm D Mason; Zsuzsanna Tabi
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

5.  Comparative assessment of the recognition of domain-specific CD163 monoclonal antibodies in human monocytes explains wide discrepancy in reported levels of cellular surface CD163 expression.

Authors:  Maciej Bogdan Maniecki; Anders Etzerodt; Søren Kragh Moestrup; Holger Jon Møller; Jonas Heilskov Graversen
Journal:  Immunobiology       Date:  2011-02-22       Impact factor: 3.144

6.  Sequential expression of macrophage anti-microbial/inflammatory and wound healing markers following innate, alternative and classical activation.

Authors:  F M Menzies; F L Henriquez; J Alexander; C W Roberts
Journal:  Clin Exp Immunol       Date:  2010-01-05       Impact factor: 4.330

Review 7.  Immune checkpoint inhibitors in NSCLC.

Authors:  Douglas B Johnson; Matthew J Rioth; Leora Horn
Journal:  Curr Treat Options Oncol       Date:  2014-12

8.  Ovarian cancer stem cells and macrophages reciprocally interact through the WNT pathway to promote pro-tumoral and malignant phenotypes in 3D engineered microenvironments.

Authors:  Shreya Raghavan; Pooja Mehta; Yuying Xie; Yu L Lei; Geeta Mehta
Journal:  J Immunother Cancer       Date:  2019-07-19       Impact factor: 13.751

9.  A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy.

Authors:  Dagmar S Lang; Daniel Droemann; Holger Schultz; Detlev Branscheid; Christian Martin; Anne R Ressmeyer; Peter Zabel; Ekkehard Vollmer; Torsten Goldmann
Journal:  Respir Res       Date:  2007-06-14

10.  M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide.

Authors:  Marie Genin; Francois Clement; Antoine Fattaccioli; Martine Raes; Carine Michiels
Journal:  BMC Cancer       Date:  2015-08-08       Impact factor: 4.430

View more
  2 in total

1.  Methods for Establishing a Renal Cell Carcinoma Tumor Spheroid Model With Immune Infiltration for Immunotherapeutic Studies.

Authors:  Leonard Lugand; Guillaume Mestrallet; Rebecca Laboureur; Clement Dumont; Fatiha Bouhidel; Malika Djouadou; Alexandra Masson-Lecomte; Francois Desgrandchamps; Stephane Culine; Edgardo D Carosella; Nathalie Rouas-Freiss; Joel LeMaoult
Journal:  Front Oncol       Date:  2022-07-28       Impact factor: 5.738

Review 2.  Biomedical Applications of Non-Small Cell Lung Cancer Spheroids.

Authors:  Julian M Rozenberg; Gleb I Filkov; Alexander V Trofimenko; Evgeny A Karpulevich; Vladimir D Parshin; Valery V Royuk; Marina I Sekacheva; Mikhail O Durymanov
Journal:  Front Oncol       Date:  2021-12-07       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.